Print

AVEG 036

A Phase I, Multicentered, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN RS gp120 and Bivalent AIDSVAX B/E rgp120 in Combination with QS21 with or without Alum in Healthy HIV-1 Uninfected Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) December 03, 1998
MN rgp120,AIDSVAX B/E Env gp120 B; Env gp120 B and E
MN rgp120 Protein
AIDSVAX B/E Protein
QS21
USA 60
NCT00001096
https://clinicaltrials.gov/show/NCT00001096